ok they say the truth, but what about breaching the confidentiality agreements they sign before getting into close enough to the ''situation''? Someone in the process does breach the agreements, no debates on that. But how can they get away?
yeah, i am tired too. Don't they violate the law by disseminating information that needs to remain confidential?
Isn't this a crime?
i wonder how do they (bloomberg, Reuters etc.) get away with that?
...Ulf Staginnus as Executive Director, Head Market Access and Pricing, Europe
old news but think, why did they hire some top notch guys of biotech before approval?
My Ans: they are expecting approval in the first go
Jul 30, 2013 16.93 17.30 16.63 17.27 384,054
Jul 29, 2013 17.14 17.23 16.84 16.90 162,555
Jul 26, 2013 16.66 17.24 16.64 17.13 172,744
Jul 25, 2013 16.43 16.85 16.31 16.84 196,488
Jul 24, 2013 16.73 16.73 16.25 16.51 222,739
Jul 23, 2013 17.03 17.03 16.65 16.68 145,104
Jul 22, 2013 17.12 17.23 16.78 17.02 138,156
Jul 19, 2013 16.80 17.08 16.61 17.05 133,188
Jul 18, 2013 17.00 17.23 16.69 16.85 112,026
Jul 17, 2013 16.97 17.04 16.69 17.02 96,278
somewhere in ECYT's presentations i read that the data they submitted for EU are very strong and include scan images of patients in which the tumour sizes were reduced. They said EU regulators were positive wrt data ECYT was submitting. In short, i can say they were very sure about conditional approval of vintafolide, etarfolatide and folic acid in FR 100% (patients having all tumours expressing Folate Receptors) before end of 2013.
I think i saw it in the analyst day presentation. More than 100 slides, but if u r looking for a de-risked investment, that presentation is a must go through. Very detailed and explains ECYT very nicely.
why the buyers are buying so hard, what are they expecting in near term?
when is the EMA decision due? when does that clock period end?
any more partnership news coming?
those who can please enlighten.
this has doubled from 9$ to 18$ over 3-4 months on NO news.
Smart guys are buying everything they can under 25 or may be 30$.
Mercks crooks? ha ha. no they can't be.
Had you observed how this traded on Q1 earning? Sold of some 15% and traded in 12-13 range. Next day Reuters disclosed cbst 20$ offer and it shot up to 16$.
Wall street doesn't know something. But only those involved in the sale process do.
OMTH was sold at 88% premium to previous day closing price. Did the street know that something was gonna happen to omth? Nope.
You never know. In fact most never know.
ucited, no disrespect intended, but your signature 'All of the above, just one man's opinion' after your every single post is also boring.
EMA filing is based on sucessful results of Phase II trial of vintafolide.
EMA allows filing with Phase II data and if all filing requirements are met, it grants a conditional approval (CA), which is then supported with phase III data (when completed) by the applicant to make it a full approval.
Conditional approval (CA) allows quicker access of a promising drug to the needful patients (for oncology=anticancer drus, CA is very frequent in europe)
I am not sure about US FDA requirements but ECYT plans to file NDA with phase III data which is due in first half of 2014.